Amir Nashat

Amir Nashat is a managing partner in Polaris’ Boston office. He joined Polaris in 2002 and focuses on investments in healthcare.

Dr. Nashat currently represents Polaris as a Director of AgBiome, CAMP4, Dewpoint Therapeutics, Fate Therapeutics (NASDAQ: FATE), Freenome, Metacrine Therapeutics, Morphic Therapeutic (NASDAQ: MORF), Scholar Rock (NASDAQ: SRRK), Selecta Biosciences (NASDAQ: SELB), Syros Pharmaceuticals (NASDAQ: SYRS) and TARIS Biomedical.

Additionally, Dr. Nashat has served as a director of Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), aTyr Pharmaceuticals (NASDAQ: LIFE), Avila Therapeutics (Celgene), Living Proof (Unilever), Pervasis Therapeutics (Shire Pharmaceuticals), Promedior Pharmaceuticals, Receptos (Celgene), and Sun Catalytix (Lockheed Martin). At Dewpoint, Living Proof, Sun Catalytix, Olivo Labs, and Jnana, Dr. Nashat has served as the company’s initial CEO. Dr. Nashat also serves on the Partners Innovation Fund, the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund as its active president.

Prior to joining Polaris, Dr. Nashat completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Dr. Nashat also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.